Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.

Smith IG, Goulder MA; Sibutramine Clinical Study 1047 Team.

J Fam Pract. 2001 Jun;50(6):505-12.

PMID:
11407998
2.

Sibutramine. A review of its contribution to the management of obesity.

McNeely W, Goa KL.

Drugs. 1998 Dec;56(6):1093-124. Review.

PMID:
9878996
3.

The efficacy and safety of sibutramine for weight loss: a systematic review.

Arterburn DE, Crane PK, Veenstra DL.

Arch Intern Med. 2004 May 10;164(9):994-1003. Review.

PMID:
15136309
4.

Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis.

Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C, Lau J.

Arch Intern Med. 2004 Jul 12;164(13):1395-404. Review.

PMID:
15249348
5.

Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.

Van Gaal LF, Wauters MA, De Leeuw IH.

Exp Clin Endocrinol Diabetes. 1998;106 Suppl 2:35-40. Review.

PMID:
9792480
6.

Modern medical management of obesity: the role of pharmaceutical intervention.

Aronne LJ.

J Am Diet Assoc. 1998 Oct;98(10 Suppl 2):S23-6. Review.

PMID:
9787732
7.

Sibutramine: a novel new agent for obesity treatment.

Ryan DH, Kaiser P, Bray GA.

Obes Res. 1995 Nov;3 Suppl 4:553S-559S. Review.

8.

Long-term pharmacotherapy for obesity and overweight.

Padwal R, Li SK, Lau DC.

Cochrane Database Syst Rev. 2004;(3):CD004094. Review.

PMID:
15266516
9.

Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Davis R, Faulds D.

Drugs. 1996 Nov;52(5):696-724. Review.

PMID:
9118819
10.

Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents.

García Díaz E, Martín Folgueras T.

Nutr Hosp. 2011 May-Jun;26(3):451-7. doi: 10.1590/S0212-16112011000300004. Review.

11.

Efficacy and safety of anti-obesity drugs in children and adolescents: systematic review and meta-analysis.

Viner RM, Hsia Y, Tomsic T, Wong IC.

Obes Rev. 2010 Aug;11(8):593-602. doi: 10.1111/j.1467-789X.2009.00651.x. Epub 2009 Nov 17. Review.

PMID:
19922432
12.

A benefit-risk assessment of sibutramine in the management of obesity.

Nisoli E, Carruba MO.

Drug Saf. 2003;26(14):1027-48. Review.

PMID:
14583064
13.

Pharmacological intervention: the antiobesity approach.

Rissanen A.

Eur J Clin Invest. 1998 Sep;28 Suppl 2:27-30. Review.

PMID:
9777325
14.
15.

Sibutramine--a review of clinical efficacy.

Lean ME.

Int J Obes Relat Metab Disord. 1997 Mar;21 Suppl 1:S30-6; discussion 37-9. Review.

PMID:
9130039
16.

[Sibutramine, an upcoming drug for weight loss acting on energy consumption and energy expenditure].

Astrup A.

Acta Med Austriaca. 1998;25(4-5):146-9. Review. German.

PMID:
9879391
17.

The use of sibutramine in the management of obesity and related disorders: an update.

Tziomalos K, Krassas GE, Tzotzas T.

Vasc Health Risk Manag. 2009;5(1):441-52. Review.

18.

Clinical studies with dexfenfluramine: from past to future.

Guy-Grand B.

Obes Res. 1995 Nov;3 Suppl 4:491S-496S. Review.

19.

Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity.

Luque CA, Rey JA.

Ann Pharmacother. 1999 Sep;33(9):968-78. Review.

PMID:
10492502
20.

Sibutramine: its mode of action and efficacy.

Finer N.

Int J Obes Relat Metab Disord. 2002 Dec;26 Suppl 4:S29-33. Review.

PMID:
12457297

Supplemental Content

Support Center